Search

Your search keyword '"Arana-Arri E"' showing total 101 results

Search Constraints

Start Over You searched for: Author "Arana-Arri E" Remove constraint Author: "Arana-Arri E"
101 results on '"Arana-Arri E"'

Search Results

1. Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months

5. A second update on mapping the human genetic architecture of COVID-19

9. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

10. Novel genes and sex differences in COVID-19 severity

11. Clinical Prediction Rule for Distinguishing Bacterial From Aseptic Meningitis

13. Quality indicators and patient satisfaction in colonoscopy

14. Risk factors for severe complications of colonoscopy in screening programs

15. Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model

16. International Variability in Gastrointestinal Decontamination With Acute Poisonings

17. Factors influencing participation in colorectal cancer screening programs in Spain

18. CRIBEA Project: Lesions Detected in Six Spanish Colorectal Cancer Screening Population Based Programmes

20. International variability in gastrointestinal decontamination with acute poisonings.

21. Factors influencing participation in colorectal cancer screening programs in Spain.

22. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model

23. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model

24. Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines

25. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model

26. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

27. CD151 identifies an NK cell subset that is enriched in COVID-19 patients and correlates with disease severity.

28. Novel risk loci for COVID-19 hospitalization among admixed American populations.

29. Increased incidence of pediatric type 1 diabetes during the pandemic in Biscay, Spain.

30. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.

31. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.

32. Violence in first-episode psychosis: evidence from an early intervention in psychosis programme.

33. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.

34. Prediction of significant coronary artery disease in acute chest pain without infarction in emergency department: MAPAC Cardio-PreTest model.

35. Flexible multiplex PCR to detect SARS-CoV-2, coronavirus OC43 and influenza A virus in nasopharyngeal swab samples.

36. Detailed stratified GWAS analysis for severe COVID-19 in four European populations.

37. Novel genes and sex differences in COVID-19 severity.

38. Gender differences in drug titration among heart failure patients with reduced ejection fraction in the ETIFIC trial.

39. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.

40. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.

41. [Effectiveness of the vagino-rectal exudate self-sampling for prenatal screening of Streptococcus agalactiae infection. GALL study].

42. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.

43. Facilitators and barriers to participation in population-based colorectal cancer screening programme from the perspective of healthcare professionals: Qualitative research study.

44. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

45. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial.

46. Effectiveness of a structured group intervention based on pain neuroscience education for patients with fibromyalgia in primary care: A multicentre randomized open-label controlled trial.

47. T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.

48. [Involvement of the Primary Healthcare professionals in the Colorectal Cancer Screening Programme of the Basque Country.]

49. Changing epidemiology of nontuberculous mycobacterial lung disease over the last two decades in a region of the Basque country.

50. Efficacy and Usability of eHealth Technologies in Stroke Survivors for Prevention of a New Stroke and Improvement of Self-Management: Phase III Randomized Control Trial.

Catalog

Books, media, physical & digital resources